[ad_1]
KUALA LUMPUR (Nov 19): Bintai Kinden Corporation, Bhd’s partner Generex Biotechnology Corporation, signed a $ 50 million development and licensing agreement with a consortium of partners in China for vaccine platform technology II. Key.
The technology is owned by NuGenerex Immuno-Oncology Inc., a subsidiary of Generex.
Bintan Kinden Managing Director Ong Choon Lui said collaboration between Generex and its partners in China would advance the li-Key vaccine development platform.
He said the agreement incorporated the first Ii-Key platform project for the development and commercialization of the coronavirus II-Key-SARS-CoV-2 (COVID-19) vaccine in China.
It also incorporated a $ 5 million initial license fee, 100 percent financing for manufacturing, development and business registration, a $ 20 million success fee for COVID-19 approval in China, and royalty payments for COVID-19 vaccine sales in China with the potential to reach several billion dollars, he said.
“The COVID-19 vaccine is the first product under this li-Key platform license.
“This bodes well for Bintai Kinden, as we have the exclusive rights to distribute, sell and market the COVID-19 vaccine in Malaysia, Brunei, Myanmar, Cambodia, East Timor, Indonesia, Laos, the Philippines, Singapore, Thailand and Vietnam. “. it said in a statement.
Ong said that Bintai Kinden also has the first right to refuse to distribute and market the vaccine in Australia, New Zealand and the global halal market.
The COVID-19 vaccine is designed as a “complete vaccine” that has the potential to induce T-cell and antibody immune responses in a very specific way that can provide protective immunity with long-lasting immune memory against the deadly virus and other pandemics. threats.
[ad_2]
